Gain an expert-led overview of the current phenylketonuria (PKU) treatment landscape in this webinar, with a focus on unmet needs and key clinical data
All webinars
Watch and listen to experts as they delve into developments in the field of phenylketonuria (PKU), as presented across live and virtual platforms
Select from our webinar content below:
|
Topic
Type
Year
▼ Sepiapterin is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC Therapeutics at pharmacovigilance@ptcbio.com.
Registration conditions differ internationally; always consult local prescribing information and/or Summary of Product Characteristics before prescribing any products.
MED-ALL-PTC923-2500012 | September 2025
MED-ALL-PKU-2500232 | December 2025